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Key Messages
1. Severe acute respiratory 
syndrome (SARS) coronavirus 
(SCoV) initiates virus 
replication in macrophages 
with the production of negative 
sense viral ribonucleic acid and 
viral protein, but such viral 
replication is abortive and no 
infectious virus is produced.
2.	 In	contrast	to	influenza	A	virus,	
infection with SCoV fails to 
induce type-1 interferons (eg 
IFN-β), which are key mediators 
of innate immune defence, but 
does lead to a strong induction 
of	proinflammatory	chemokines	
(eg IP10). 
3. Sub-neutralising antibody 
to SCoV does not lead to 
the mediation of antibody-
dependent enhancement of 
SCoV viral replication in 
macrophages.
4. Microarray analysis of SCoV 
infected	 cells	 identifies	 novel	
pathways including cytokines 
and chemokines and apoptotic 
pathways that are differentially 
activated by SCoV, which may 
be important in the pathogenesis 
of SARS, and deserve further 
studies.
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Introduction
A	 novel	 coronavirus	 was	 identified	 as	 the	 causative	 agent	 of	 severe	 acute	
respiratory syndrome (SARS).1 Compared with common respiratory viral 
infections, SARS is unusually severe, with an overall fatality rate of about 
10%.	The	SARS	coronavirus	 (SCoV)	 causes	 a	 range	 of	 disease	 from	flu-like	
symptoms and viral pneumonia to acute respiratory distress syndrome and death. 
The previously known human coronaviruses 229E (HCoV-229E) and OC43 have 
only been linked with the common cold. However, several animal coronaviruses 
have resulted in severe animals diseases of the respiratory or gastrointestinal 
tract or disseminated infections. 
 Macrophages are key cells for host defence and are abundant within all 
tissues of the body, including the respiratory system. They are potent producers 
of cytokines that are crucial components of innate immunity and potential 
mediators of immunopathology. Genetic resistance to strains of the coronavirus 
mouse hepatitis virus is associated with the ability of the virus to replicate in 
macrophages.2 In contrast, feline infectious peritonitis is a disease caused by a 
coronavirus in which prior immunity or passive antibodies increase the severity 
of the disease.3 In this disease, macrophages are the main target cells for virus 
replication, and antiviral antibodies enhance the replication of the virus in 
macrophage cultures in vitro. This has led to concerns about whether antibody-
mediated enhancement of disease may be relevant to the pathogenesis of SARS. 
Aims and objectives
1. Establish an in vitro model of SCoV infection of human primary 
macrophages;
2.	 Define	 the	 gene	 expression	 profile	 of	 SCoV-infected	 macrophages	 and	
compare	it	with	human	coronavirus	229E	and	influenza	A	(H1N1);	and
3.	 Define	the	effect	of	antibody	on	neutralisation	or	enhancement	of	virus	entry	
and replication.
Methods
This study was conducted from June 2005 to November 2006.
In vitro model of SCoV infection in macrophages and gene expression 
profiling
Using	 microarray	 gene	 expression	 profiling,	 we	 compared	 host	 response	 of	
primary human macrophages to infection with SCoV (strain HK39849), HCoV-
229E,	 and	 influenza	A	 virus	 (A/HK/54/98).	 The	 study	 was	 performed	 using	
macrophages derived from peripheral blood mononuclear cells of three different 
donors. The cells of each donor were subjected to microarray analysis after 
infection with each virus for 1, 3, and 6 hours. Ribonucleic acid (RNA) extracted 
from each macrophage preparation was examined for human genome-wide gene 
expression with a GeneChip Human Gene 1.0 ST Array (Affymetrix, Santa 
Clara, USA) by the use of oligonucleotide probe sets, which spread across the 
full length of each gene in order to interrogate 28 869 genes (Genome Research 
Centre, The University of Hong Kong). Microarray data was normalised using 
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an ExonRMA summarisation algorithm on probe sets and 
baseline transform to a medium of all samples using the 
GeneSpring GX 9.0.5 software. By performing principal 
components analysis looking for outlier samples falling 
distal	to	the	dataset	at	large	and	using	filters	on	flags,	quality	
control of sample levels was attained. Statistical analysis 
entailed a 2-way ANOVA test with a P-value cut-off of 
<0.05. Differential expression of genes to corresponding 
mock	entities	was	selected	with	fold	change	of	≥1.5.	Genes	
of individual pathways of interest were further studied 
using	 quantitative	 real-time	 polymerase	 chain	 reaction	
(RT-PCR) methods. Protein levels of key mediators were 
confirmed	 using	 enzyme-linked	 immunosorbent	 assays	
(ELISA) (R&D Systems, Minneapolis, USA), according to 
the manufacturer’s instructions. Culture supernatants were 
ultraviolet-irradiated for 20 min to inactivate infectious 
viruses prior to assay in a biosafety level-3 facility. Previous 
experiments	 have	 confirmed	 that	 cytokine	 levels	 are	 not	
affected by the dose of ultraviolet radiation used.4 
Immune enhancement assay of SCoV replication in 
macrophages
We investigated the effect a human monoclonal (CR3014, 
a gift from Crucell Holland BV, Leiden, The Netherlands) 
and polyclonal (convalescent SARS serum) antibody 
to SCoV on the entry and replication of SCoV in human 
macrophages. Serial dilutions of the respective antibody 
or	 relevant	 control	 serum	were	 mixed	 with	 a	 fixed	 dose	
of SCoV and infected onto human macrophages. Samples 
of the culture supernatants were collected at days 0, 1, 2, 
3, 5, and 7 post-infection and titrated for virus infectivity. 
Ribonucleic acid was isolated from infected macrophages 
at 6 and 24 hours post-infection using the RNeasy Mini kit 
(Qiagen, Valencia, USA) according to the manufacturer’s 
instructions.	Quantification	of	positive-	and	negative-strand	
viral	RNA	was	performed	by	quantitative	RT-PCR	targeting	
the ORF1b gene, as described previously.5 The SCoV RNA 
levels were normalised for the levels of β-actin mRNA.
Results
SCoV infection of macrophages
After infection of macrophages with SCoV, there was 
an increase in the copy numbers of both the positive 
and negative RNA strands of the SCoV ORF-1b and 
nucleocapsid	genes	over	the	first	few	hours	after	infection.	
Viral RNA levels in macrophages peaked at modest levels at 
about 6 h post-infection, but in FRhK-4 cells they continued 
to increase, reaching much higher absolute levels. A mouse 
monoclonal antibody (4D11) was used to demonstrate 
nucleoprotein expression in SCoV-infected macrophages. 
More than 90% of macrophages showed nucleoprotein 
expression when infected at a multiplicity of infection of 
one to two. However, no infectious virus was detected in 
the supernatant of virus-infected macrophages for up to 7 
days post-infection, indicating that virus infection of these 
cells was abortive. In contrast, virus-infected FRhK-4 cells 
produced infectious virus titres up to 105 in 50% tissue 
culture	 infective	 doses/ml	 (data	 not	 shown),	 peaking	 at	
about 2 to 3 days post-infection.
Microarray analysis
In order to identify host genes that are affected by SCoV 
and thus account for its virulence, we compared the gene 
expression	 profile	 of	 SCoV-infected	 macrophages	 with	
that	 of	 low	 pathogenic	 viruses	 (influenza	 H1N1	 and	
HCoV 229E) at various time points post-infection. Figure 
1 illustrates the number of genes differentially affected by 
SCoV	infection	in	comparison	with	influenza	A	or	HCoV	
229E.	The	proportion	of	genes	uniquely	affected	by	SCoV	
in comparison to H1N1 or HCoV 229E or both remained 
consistent at 77% at 1 and 3 h post-infection, but was 
down to 35% at 6 h post-infection. Figure 2 summarises 
selected microarray data presented as fold-change of gene 
expression in comparison to mock infected cells for innate 
immune markers at 1, 3 and 6 hours post-infection with 
SCoV,	HCoV229E,	and	influenza	A	H1N1.	Notably,	IFN-
β and -α-1 induction appears delayed or absent in SCoV- 
or HCoV 229E-infected macrophages. IP-10 induction is 
strongly induced at 1 and 3 hours by SCoV, while IL-8 is 
differentially down-regulated by SCoV (Fig 3). Apoptotic 
and anti-apoptotic pathways were also differentially 
activated in SCoV infected macrophages (data not shown). 
 Microarray analysis also suggests that other 
proinflammatory	 cytokines	 such	 as	 TNF,	 CCL2/MCP-
1,	 CXCL10/IP-10	 were	 strongly	 induced.	 Quantitative	
RT-PCR	analysis	 confirmed	an	 early	 induction	of	 several	
chemokines,	such	as	CXCL10/IP-10	and	CCL2/MCP-1,	in	
SCoV-infected	macrophages.	The	ELISAs	for	CXCL10/IP-
10	and	CCL2/MCP-1	in	macrophage	culture	supernatants	
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Fig 1. Microarray analysis of host genes affected by SCoV-
infected macrophages
Gene expression profile of SCoV-infected, primary monocyte–
derived macrophages is compared with that of H1N1 and HCoV 
229E infections at 1, 3, and 6 hours post-infection. Genes with 
level change of 1.5 folds are regarded as affected. Genes that are 
affected by SCoV infection as well as by H1N1, HCoV 229E, or 
both are shown (white bar), with the proportion of the genes that 
are affected by SCoV indicated (black bar)
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Fig 2. Microarray data showing fold change in gene expression of selected innate immune response genes differentially affected 
by SCoV-infected macrophages
Gene expression profile of SCoV-infected, primary monocyte–derived macrophages is compared with that of H1N1 and HCoV 229E 
infections at 1, 3, and 6 hours post-infection. Composite data from three different donors is presented. Gene expression is denoted with 
reference to that in mock infected cells
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confirmed	 that	SCoV	induced	CXCL10/IP-10	and	CCL2/
MCP-1	secretion	in	macrophages	in	the	first	few	hours	after	
infection. 
 In collaboration with a research group showing that 
SCoV Orf3a has apoptotic activity, we investigated the 
function of SCoV3a in SCoV-infected cells. The SCoV3a 
was localised to the Golgi region and interacted with 
caveolin 1 (according to yeast two hybrid analysis). There 
was evidence that caveolin 1 may be found in SCoV particles 
(data not shown). This is relevant to the microarray data 
where SCoV differentially activated a number of pro- and 
anti-apoptotic genes.   
SCoV does not replicate in human macrophages in 
the presence of mAb CR3014 or convalescent serum
The SCoV did not replicate in primary human macrophages 
to produce infectious virus at measurable titres and 
the addition of serial dilutions of a human monoclonal 
antibody to SARS CoV spike (mAb CR3014). Serum from 
a convalescent SARS patient did not convert this abortive 
infection to a productive one. Productive virus replication 
was	assayed	by	cell	culture	titration	and	by	strand-specific	
RT-PCR assays to detect the negative sense (replication 
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Fig 3 (a). Lack of induction of IFN-ß gene expression in SCoV-
infected macrophages
Levels of IFN-ß mRNA are determined by quantitative real-time 
polymerase chain reaction. Macrophages are infected with SCoV 
( ), HCoV-229E ( ), and influenza A (H1N1) virus ( ) at a 
multiplicity of infection of one to two, and RNA is extracted at 3, 
6, and 15 h post-infection. The SCoV-infected macrophages does 
not induce IFN-ß at any of the three time points, in contrast to 
infections with influenza A (H1N1) and HCoV-299E viruses
Fig 3 (b). Levels of CXCL10/IP-10 and CCL2/MCP-1 are elevated in SCoV-infected macrophages
Macrophages are infected with SCoV at a multiplicity of infection of one to two. Ribonucleic acid is extracted at 3, 6, and 15 h post-infection, 
and the levels of mRNA for CXCL10/IP-10 and CCL2/MCP-1 are determined by quantitative real-time polymerase chain reaction (top). 
Aliquots of the culture supernatant are taken at 6, 15, and 24 h post-infection, and the levels of secreted CXCL10/IP-10 and CCL2/MCP-1 
are determined by specific enzyme-linked immunosorbent assays (bottom). The means±standard deviations of duplicate cultures from the 
same donor are representative of three independent experiments with similar results. SCoV infection ( ) of macrophages induces higher 
levels of gene expression and secretion of CXCL10/IP-10 and CCL2/MCP-1 than does mock infection ( )
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intermediate) and positive sense viral RNA. With or without 
monoclonal or polyclonal antibody, macrophages took up 
SCoV, but this uptake did not lead to the productive virus 
replication and release of infectious virus.
Discussion
This	 study	 confirmed	 that	 virus	 gene	 transcription	 and	
translation were initiated in infected macrophages and 
that the block in productive virus replication occurred 
subsequently.	 Although	 double-stranded	 RNAs	 (which	
are potent inducers of type-1 interferon) and viral protein 
were expressed in SCoV-infected macrophages, there was 
no detectable IFN-β response in these cells. Others have 
reported	similar	findings	in	other	cell	types	(eg	epithelial).6 
The SCoV also failed to induce IL-28 and -29, which are 
two other recently discovered interferon-like cytokines 
with antiviral activities.7 In contrast, both HCoV-229E and 
influenza	A	virus	induced	IFN-β as well as IL-28 and IL-
29 in macrophages, although such induction was delayed 
in	HCoV	229E	in	comparison	with	influenza	A.	This	lack	
of innate immune defences may explain the progressive 
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increase of viral load in the nasopharyngeal secretions 
up to week 2 of SARS infection, in contrast to other 
respiratory	 infections	such	as	HCoV-229E	and	 influenza	
A virus.8  
	 The	SCoV	protein	nsp1	has	been	identified	as	a	putative	
interferon antagonist but its signalling pathways are 
unclear.
	 Chemokines	such	as	CXCL10/IP-10	and	CCL2/MCP-
1	were	up-regulated	 in	macrophages	by	SCoV.	CXCL10/
IP-10	 and	 CCL2/MCP-1	 are	 chemotactic	 for	monocytes/
macrophages,	which	are	the	predominant	inflammatory	cell	
type in the lungs of SARS patients. We (unpublished data) 
and others9	have	found	significantly	elevated	blood	levels	
of	CXCL10/IP-10	and	CCL2/MCP-1	in	SARS	patients	and	
that	 both	 chemokines	 were	 significantly	 elevated	 during	
the	 early	 stage	 of	 the	 illness.	 The	 chemokines	 CCL3/
macrophage	 inflammatory	 protein	 1,	 CCL7/MCP-3,	 and	
CCL8/MCP-2	 were	 induced	 by	 SCoV	 according	 to	 the	
microarray analysis, and their biological effects were similar 
to	CCL2/MCP-1.	Therefore,	the	members	of	the	monocyte	
chemotactic	protein	and	macrophage	inflammatory	protein	
can	synergistically	induce	a	cycle	of	monocyte/macrophage	
recruitment	 and,	 potentially,	 monocyte/macrophage-
induced immunopathology. 
 In this study, we also addressed the potential problem of 
antibody-dependent enhancement (ADE), which is a well-
recognised phenomenon observed in infections with other 
coronavirus—feline infectious peritonitis virus. Given 
that ADE in feline infectious peritonitis virus infection is 
mediated by increased macrophage uptake of virus in the 
presence of neutralising antibody, we performed human 
macrophage infectivity assays in the presence of serial 
dilutions of CR3014 and human convalescent serum. 
The addition of varying concentrations of CR3014 or 
convalescent SARS serum to SCoV did not convert the 
abortive infection into a productive one. This reduced the 
likelihood that ADE in macrophages will be observed in 
vivo after passive immunisation in a manner analogous to 
that with feline infectious peritonitis. 
Conclusions
The lack of a type-1 interferon response despite a strong 
induction of macrophage tropic chemokines may explain 
aspects of the pathogenesis of SARS. Although putative 
viral proteins such as the nsp1 have been implicated as 
interferon antagonists in SCoV, the signalling mechanisms 
that underlie this suppression of interferon remain unknown 
and deserve further research. The apparent inability of 
SCoV to trigger interferon responses may provide support 
for the use of interferon treatment for SARS. 
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